Xeris Biopharma Holdings Q2 EPS $(0.14) Misses $(0.13) Estimate, Sales $36.89M Beat $34.84M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings reported Q2 losses of $(0.14) per share, missing the analyst consensus estimate of $(0.13) by 7.69%. However, the company's quarterly sales of $36.89 million beat the estimate of $34.84 million by 5.89%. This represents a 26.32% increase in losses and a 46.05% increase in sales compared to the same period last year.
August 08, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Xeris Biopharma's Q2 earnings per share missed estimates, but sales exceeded expectations. This mixed result could lead to uncertainty in the market.
Xeris Biopharma's Q2 earnings per share missed the analyst consensus, which could negatively impact the stock. However, the company's sales exceeded estimates, which could have a positive effect. The mixed results could lead to uncertainty among investors, potentially causing short-term volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100